Status:
RECRUITING
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
Chang Gung Memorial Hospital
China Medical University Hospital
Conditions:
Acute Kidney Injury
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Acute kidney disease (AKD) happens between 7 and 90 days after an initial kidney injury (AKI). This period is crucial because it can determine whether the condition worsens into chronic kidney disease...
Eligibility Criteria
Inclusion
- Age ≥ 18 years and \< 80 years
- Diagnosed with acute kidney disease
- Estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73m²
- Albuminuria \> 100 mg/g or proteinuria \> 300 mg/g (adjusted by urine creatinine)
- Diagnosed with diabetes or chronic kidney disease
Exclusion
- Received sodium-glucose cotransporter 2 (SGLT2) inhibitors within 28 days prior to enrollment
- Patients with type 1 diabetes
- Receiving aggressive immunosuppressive therapy for glomerulonephritis
- Obstructive nephropathy
- Polycystic kidney disease
- Malignancy within 3 months or expected to undergo aggressive treatment such as chemotherapy, radiation therapy, immunotherapy, or targeted therapy in the future
- Pregnant or breastfeeding women
- Clinically assessed as not having recovered from acute kidney injury
- Clinically assessed as at high risk for complications related to SGLT2 inhibitors
Key Trial Info
Start Date :
November 21 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT06528405
Start Date
November 21 2024
End Date
December 1 2027
Last Update
January 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan